Physician profile
David E Nagata
NPI 1750371324
$3,291.82
in general payments reported to CMS, 2019-2025
43 companies · $844 in 2025
The $844 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $17.87 · 2022: $63.96 · 2023: $1,028 · 2024: $1,039 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,910.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $359.62 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $342.03 | 2019-2025 | Repatha, Otezla, Prolia |
| Astrazeneca Pharmaceuticals LP | $330.58 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Sumitomo Pharma America, INC. | $216.63 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $209.53 | 2023-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.07 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Abbott Laboratories | $167.01 | 2019-2025 | Jot Dx, Diamondback Coronary, Aveir |
| Novo Nordisk INC | $106.04 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $101.30 | 2022-2023 | Xarelto |
| Edwards Lifesciences Corporation | $89.92 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lilly USA, LLC | $82.80 | 2023-2025 | Jardiance, Kisunla |
| Inspire Medical Systems, INC. | $81.38 | 2023-2025 | Inspire |
| Boston Scientific Corporation | $76.25 | 2023-2025 | Watchman Access System, Watchman Flx |
| Heartflow, INC. | $74.46 | 2024 | |
| Scilex Pharmaceuticals INC. | $67.74 | 2023-2024 | Ztlido |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $60.27 | 2023-2025 | |
| Astellas Pharma US INC | $57.97 | 2025 | Veozah |
| Medtronic, INC. | $55.32 | 2024-2025 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Abiomed | $53.67 | 2023 | Impella |
| Exact Sciences Corporation | $39.52 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $33.99 | 2023-2024 | |
| Nevro Corp. | $33.77 | 2023 | Senza |
| Novartis Pharmaceuticals Corporation | $33.66 | 2023 | |
| Eisai INC. | $27.22 | 2024 | |
| Sanofi Pasteur INC. | $26.90 | 2019 | |
| Phathom Pharmaceuticals, INC. | $25.27 | 2025 | Voquezna |
| Esperion Therapeutics, INC. | $24.39 | 2024 | Nexletol |
| Corcept Therapeutics | $24.32 | 2025 | Korlym |
| Cmp Pharma, INC. | $24.08 | 2024 | Liqrev, Carospir, Tadliq |
| Bayer Healthcare Pharmaceuticals INC. | $23.22 | 2023 | |
| Aimmune Therapeutics, INC. | $22.69 | 2025 | Zenpep |
| Dexcom, INC. | $22.44 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $22.37 | 2023 | Gvoke Hypopen |
| Inogen, INC. | $20.26 | 2025 | |
| Paratek Pharmaceuticals, INC. | $19.84 | 2023 | Nuzyra |
| Lucid Diagnostics INC. | $18.60 | 2023 | |
| Tanabe Pharma America, INC. | $17.94 | 2023 | |
| Medtronic Vascular, INC. | $17.87 | 2020 | |
| Painteq LLC | $17.25 | 2024 | Painteq |
| Merck Sharp & Dohme LLC | $16.40 | 2019 | |
| Axonics, INC. | $15.87 | 2024 | Axonics |
| Impulse Dynamics (USA) INC. | $15.59 | 2023 | Optimizer |
| Smith+Nephew, INC. | $12.77 | 2023 | Redapt, Journey II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nagata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.